Helicobacter pylori infection
Conditions
Interventions
placebo group:maltodextrin+Soy protein
Lactobacillus crimpG14-5M group:Lactobacillus crimpG14-5M
Lactobacillus rhamnosus JS-SZ group:Lactobacillus rhamnosus JS-SZ
Lactobacillus helveticus D-7-S146 group:Lactobacillus helveticus D-7-S146
Sponsors
The People's Hospital of Tinghu District, Yancheng City
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1 Helicobacter pylori infection was diagnosed within 12 months before enrollment through 13c-urea breath test, rapid urease test or histological examination; 2 Aged 18 to 65 years, half male and half female; 3 The general health condition is good, whether eradication treatment is needed according to the judgment of investigators; 4 The ability to understand the learning requirements and those who promise to cooperate with the researchers during the whole experimental period; 5 Volunteers who willing to provide written informed consent, basic information survey; 6 Volunteers who haven't received anti-helicobacter pylori therapy before.
Exclusion criteria
Exclusion criteria: 1 History of gastrointestinal surgery (except appendectomy); 2 Any contraindications eradication treatment; 3 Pregnant or nursing women; 4 Prior to the eradication of helicobacter pylori treatment, there were any historical serious diseases (severe cardiovascular, endocrine, liver and kidney dysfunction, etc.); 5 Patients will be excluded if they take probiotics, antibiotics or research products in the previous month; 6 Having mental illness that may cause difficulties in cooperation; 7 Patients who lack of self-judgment ability; 8 Alcohol or drug abusers; 9 Participants in other clinical trials; 10 Unwilling or unable to provide the written informed consent on attending the study after the researcher has informed the purpose, process and possible risks of the research ; 11 Do not conform to the requirements of the study or the researchers think that they should not take part in research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 13C-UBT;Gastrointestinal Symptom Rating Scale;anti-Hp IgG;intestinal microflora;Gastrin-17;Pepsinogen I/Pepsinogen II;inflamatory cytokines; | — |
Countries
China
Contacts
Public ContactWenwei Lu
Jiangnan University
Outcome results
None listed